Francesco Forconi, MD, DM, PhD, FRCPath

Cancer Sciences, Faculty of Medicine, University of Southampton, United Kingdom

N/A

Poster(s):

• 1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL

• 3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)